Skip to main content
Download PDF
Download ePub

Severity of COVID-19 infection in patients with COVID-19 combined with diabetes

Journal of Health, Population and Nutrition volume 43, Article number: 55 (2024) Cite this article

Abstract

Purpose

This study aimed to analyse the correlation between blood glucose control and the severity of COVID-19 infection in patients with diabetes.

Methods

Clinical and imaging data of a total of 146 patients with diabetes combined with COVID-19 who visited our hospital between December 2022 and January 2023 were retrospectively collected. The patients were divided into the ‘good blood glucose control’ group and the ‘poor blood glucose control’ group based on an assessment of their blood glucose control. The clinical data, computed tomography (CT) appearance and score and the severity of COVID-19 infection of the two groups were compared, with the severity of COVID-19 infection being the dependent variable to analyse other influencing factors.

Results

The group with poor blood glucose control showed a higher lobar involvement degree and total CT severity score (CTSS) than the group with good blood glucose control (13.30 ± 5.25 vs. 10.38 ± 4.84, p < 0.05). The two groups exhibited no statistically significant differences in blood lymphocyte, leukocyte, C-reaction protein, pleural effusion, consolidation, ground glass opacity or crazy-paving signs. Logistic regression analysis showed that the total CTSS significantly influences the clinical severity of patients (odds ratio 1.585, p < 0.05), whereas fasting plasma glucose and blood glucose control are not independent factors influencing clinical severity (both p > 0.05). The area under the curve (AUC) of CTSS prediction of critical COVID-19 was 0.895 with sensitivity of 79.3% and specificity of 88.1% when the threshold value is 12.

Conclusion

Blood glucose control is significantly correlated with the CTSS; the higher the blood glucose is, the more severe the lung manifestation. The CTSS can also be used to evaluate and predict the clinical severity of COVID-19.

Introduction

The 2019 novel coronavirus pneumonia (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus, which is highly susceptible to mutation [1]. Most patients contracting the virus experience mild to moderate respiratory diseases and can recover with symptomatic treatment. A relatively small number develop acute respiratory distress syndrome, multiple organ failure or even death, as observed mainly in older patients with underlying medical conditions [2]. The evidence suggests that elderly patients with chronic diseases such as hypertension, carotid artery diseases and diabetes are more susceptible to COVID-19 [3,4,5], and according to China’s census data, nearly half of the older population (in which the average life expectancy is continually increasing) suffer from diabetes [6].

Previous research has shown that, compared with normal infected individuals, patients with diabetes exhibit more severe conditions in terms of clinical course and chest imaging and are more likely to develop critical COVID-19 [5, 7, 8]. In addition, those with poor blood glucose control have a worse prognosis [9]. Diabetes has become a major risk factor for poor prognosis in patients with COVID-19 [10]. The severity of diabetes is associated with a rise in inflammation biomarker levels, leukocytosis and neutrocytophilia and is also an independent factor associated with the death of patients [11]. Therefore, it is necessary to carry out an in-depth exploration of the correlation between blood glucose control and the severity of lung infection to guide the clinical application of medication and promote prevention publicity, thereby improving patients’ quality of life.

Materials and methods

Research participants

A total of 146 patients with diabetes combined with COVID-19, including 87 men and 59 women, who visited the researchers’ hospital between December 2022 and January 2023 were retrospectively identified. According to their fasting plasma glucose (FPG) and glycated haemoglobin (HbA1c) levels upon admission, the patients were divided into the ‘good blood glucose control group’ (PFG ≤ 7 mmol/L and HbA1c < 7.0%) and the ‘poor blood glucose control group’ (PFG > 7 mmol/L or HbA1c ≥ 7.0%), which consisted of 53 and 93 patients, respectively. Based on the latest version of the Guidelines on Diagnosis and Treatment of Novel Coronavirus Pneumonia [4], the two groups of patients were clinically classified into common and critical types.

The inclusion criteria were as follows: (1) The reverse transcription polymerase chain reaction (RT-PCR) tested positive for COVID-19; (2) the latest recognised diabetes diagnostic criteria [7] were met: the FPG level measured in venous blood was ≥ 7 mmol/L, 2 h postload or random blood glucose ≥ 11.1 mmol/L and HbA1c ≥ 6.5%.

The exclusion criteria were as follows: (1) Previous history of lung tumours or lung surgery; (2) previous history of pulmonary tuberculosis, chronic obstructive pulmonary disease, pulmonary interstitial fibrosis or heart failure; (3) re-positive result in the RT-PCR test; (3) poor image quality that was inappropriate for evaluation.

Clinical data

Patients’ basic information, including gender, age, white blood cell and lymphocyte counts, C-reactive protein (CRP) level, PFG, HbA1c and chest computed tomography (CT) scan images within 2 days of admission, was collected.

Imaging data

Computed tomography scan

A plain chest CT scan from the apex to the base of the lungs was performed during the end-inhale phase by Philips 64-slice spiral CT. The parameters of the scan were as follows: tube voltage– 120 kV; tube current– 150 mA; slice thickness– 5 mm; spiral pitch– 1.0; lung window– (width 1,400 Hu, level − 600 Hu); mediastinal window– (width 400 Hu; level 40 Hu).

The CT severity score (CTSS) was employed to evaluate the severity of patients’ images and was based on the degree of lobar involvement (0–25). Image processing: The CT images of all cases were evaluated by two radiologists at a level of attending physician or above (without knowing clinical information) to determine whether there was (1) ground glass opacity (GGO); (2) consolidation; (3) pleural effusion; (4) crazy-paving signs. All CT images were uploaded to the Deepwise MetAI system to quantitatively score the affected area of each lung lobe against the following criteria: 0 affected (score 0), < 5% affected (score 1); 5–25% affected (score 2); 26–49% affected (score 3); 50–75% affected (score 4) and > 75% affected (score 5). Each lung lobe scores 0–5, giving a total score of 0–25.

Statistical analysis

Statistical analysis was performed using the SPSS 26.0 software, where categorical variables were expressed as frequencies and percentages, continuous variables were expressed as mean values and quantitative data with non-normal distribution were calculated by quartiles. The chi-squared test was used to analyse categorical variables, the t-test for continuous variables with normal distribution and the rank sum test for those with non-normal distribution. Logistic regression analysis was performed to detect independent factors influencing clinical severity. A p-value of < 0.05 was considered statistically significant.

Results

Clinical data comparison

A total of 146 cases were included in this study, with an average age of 74 (65–83) years. Table 1 shows the statistical results of the clinical data of the two groups of patients. Specifically, the good blood glucose control group and poor blood glucose control group show no statistically significant differences (p ≥ 0.05) in gender, age, blood lymphocyte, leukocyte and CRP; the two groups showed a statistically significant difference in clinical classification, with the number of critically ill patients in the poor blood glucose control group higher than those in the good blood glucose control group. The group with poor blood glucose control showed a higher lobar involvement degree and total CTSS than the group with good blood glucose control (13.30 ± 5.25 vs. 10.38 ± 4.84, p < 0.05).

Table 1 Clinical data of two groups
Full size table

Computed tomography appearance and score comparison

The two groups of patients exhibited no statistically significant differences (p > 0.05) in the presence of pleural effusion, consolidation, GGO and crazy-paving signs in CT images, although the scores of lung lobes were significantly different across the two groups (Table 2). The CTSS and FPG level were significantly positively correlated, with p = 0.007, correlation coefficient r = 0.221 and a moderate level of correlation; the total CTSS and diabetes blood glucose control were significantly positively correlated, with p = 0.001and r = 0.268, indicating a significantly positive correlation and a moderate level of correlation (Fig. 1).

Table 2 Chest CT index of the two groups
Full size table
Fig. 1
figure 1

CTSS score in bad control and good control of blood group and the diffrerence between two group

Full size image

Logistic regression analysis of independent factors influencing clinical severity

The total CTSS significantly influences patients’ clinical severity, p < 0.05. Further, the influence coefficient is 0.461, indicating that the higher the total CTSS is, the more likely the patients are to have a critical clinical manifestation. For every 1-point increase in the total CTSS, the patients are 1.585 times more likely to exhibit a critical clinical manifestation. Patients’ FPG level and blood glucose control are not independent factors influencing clinical severity, p > 0.05 (Fig. 2).

Fig. 2
figure 2

Logistic regression analysis of independent factors influencing clinical severity. The medel was adjusted for age, gender, HbA1c, FPG, CTSS and CRP

Full size image

Computed tomography severity score evaluation and prediction of COVID-19 clinical classification

The area under the curve (AUC) of CTSS prediction of critical COVID-19 was 0.895 with sensitivity of 79.3% and specificity of 88.1% (Fig. 3) when the threshold value is 12 [12].

Fig. 3
figure 3

The ROC curve of clinical classification prediction by CTSS score

Full size image

Discussion

Our results showed that chest CT imaging is a reliable testing method for COVID-19 evaluation; the higher the blood glucose level is, the more evident the lung inflammation and the more severe the clinical manifestation.

The proportion of patients with diabetes has been growing in the older population [13]. High blood glucose causes an increase of dicarbonyl molecules in the human body, inhibits the antibacterial and immune function of β-defensins and increases the susceptibility of patients, particularly among those with uncontrolled or poorly controlled blood glucose [14]. Previous studies have shown that high blood glucose reduces peripheral blood lymphocytes and increases leukocytes in patients with COVID-19, leading to immune system overactivation and more severe clinical symptoms [5, 15]. Although some of the research indicates that neutrophils and leukocytes help distinguish asymptomatic and moderate COVID-19 [16], this study found that the differences in lymphocytes and leukocytes among patients are not statistically significant.

According to the latest version of the Guidelines on Diagnosis and Treatment of Novel Coronavirus Pneumonia, the diagnostic criterion for COVID-19 is a positive RT-PCR test; however, the detecion takes about one day and the production of test kits is limited. Comparatively, a chest CT scan is an important tool for the rapid screening and initial diagnosis of COVID-19; given its convenience, it can serve as a predictive indicator to evaluate illness severity and clinical prognosis [12, 17, 18] and help in the timely adjustment of patients’ diagnosis and treatment [19]. Most patients show abnormal manifestations of the lungs 2–3 days after contracting COVID-19. In the early stage of the disease, the virus tends to invade peripheral blood vessels and bronchioles, causing interstitial changes in lung tissue, such as interstitial inflammatory oedema and interlobular septal thickening, leading to a rise in pressure of lung parenchyma and exudation of fibrinous and high-protein mucus within bronchiole and thus the formation of GGO and halo sign in the subpleural lung region. Over time, interlobular septal thickening further causes the formation of crazy-paving signs, restricting the absorption of alveolar exudate and causing alveolar consolidation and in serious cases, even diffuse alveolar damage, eventually leading to a white lung and pleural effusion in some patients [18, 20, 21]. A review of relevant literature reveals that compared with patients without diabetes, patients with diabetes show more evident inflammation on chest CT and those with poor blood glucose control exhibit more severe lung damage [3, 5]. Similar to previous studies, the majority of patients in this experiment demonstrated GGO and lung consolidation on their CT appearance, and a few even showed pleural effusion and crazy-paving signs. However, the differences in these changes are statistically insignificant between the two groups, which may be attributed to the small number of cases and good treatment received by most patients during the early onset of the disease.

Since the outbreak of COVID-19, chest CT imaging has played an important role in evaluating infected patients. Pan et al. [22] proposed semiquantitative CTSSs based on the degree of lobar involvement (0–25). We employed the CTSS to evaluate the severity of patients’ images (Fig. 4). Previous research shows that patients with poor blood glucose control have a significantly higher CTSS than those with good blood glucose control [23, 24] because high blood glucose inhibits the immune system and increases the generation of inflammatory factors, causing more severe chest manifestations after the patient contracts viral pneumonia. Statistics show that patients with diabetes have a significantly higher CTSS than those who are not diabetic, and the higher the blood glucose level is on the date of admission, the more severe the lung damage [7, 25, 26]. Our results indicate that blood glucose control is significantly positively correlated to CTSS; patients with poorly controlled blood glucose have higher scores, and lesions commonly involve the lower lobes and peripheral zones of both lungs, further validating that blood glucose affects lung manifestations of the disease. However, blood glucose control and FPG level cannot be treated as independent predictors of clinical severity, and the relationship between blood glucose and COVID-19 requires further exploration. The CTSS can be used to evaluate and predict clinical classification and, in the meantime, offers some accuracy in predicting patient mortality [27], reminding us of the necessity of imaging examination in the diagnosis and treatment of patients with COVID-19. One Iranian study found no significant differences in clinical outcomes and chest CTSSs between patients with diabetes with good and poor blood glucose control [28], which is inconsistent with the findings of this study. This may be attributed to the fact that the former study failed to confirm the diagnosis with test kits and only referred to clinical characteristics and chest imaging manifestation when including patients in the positive group, as well as potential physical differences between Iranian and Chinese patients [29].

Fig. 4
figure 4

Patients’ chest CTSS: Figure A shows mild pneumonia in patients with scattered multiple ground glass opacities in both lungs, the right upper lobe lesion accounting for 13.9% of lobe volume and a CTSS score of 2. Figure B shows a diffuse exudative consolidation scattered in both lungs, with the left upper lobe lesion accounting for 91.4% of lobe volume and a CTSS score of 5. (A) male, 48 years old, a history of diabetes for 3 years, regular medicine with well-controlled blood glucose. (B) female, 44 years old, with history of diabetes for 5 years, irregular medication and poor blood glucose control

Full size image

Our study also had some limitations. First, the retrospective design with a relatively small sample size may not be adequate to get reliable results. Moreover, COVID-19, as a newly discovered disease, still has many mysteries that remain in dispute, including the assessment of severity. Further large-scale prospective design studies should be conducted to explore the characteristics of COVID-19 and its relationship with diabetes. Moreover, we only included patients with diabetes; the results in patients without diabetes or with other diseases should be explored and the number of patients with COVID-19 infection was not clear in the research hospital.

In summary, chest CT imaging is a reliable testing method for COVID-19 evaluation; the higher the blood glucose level is, the more evident the lung inflammation and the more severe the clinical manifestation. This indicates that clinical patients should first receive a CT scan upon admission to evaluate their initial condition, and imaging appearances should be analysed thoroughly. Targeted treatment should be administered, and publicity and education activities should be implemented aiming to popularise among patients with diabetes the necessity of controlling their blood glucose and encouraging them to make an active effort to keep healthy and follow appropriate diets, thus improving their quality of life.

Data availability

All data generated or analyzed during this study are included in this published article.

References

  1. Sarkar A, Omar S, Alshareef A, Fanous K, Sarker S, Alroobi H, et al. The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: a systematic review. Hum Vaccin Immunother. 2023;19(1):2212568. https://doi.org/10.1080/21645515.2023.2212568

    Article  PubMed  PubMed Central  Google Scholar 

  2. Zhang J, Wang X, Jia X, Li J, Hu K, Chen G, et al. Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China. Clin Microbiol Infect. 2020;26(6):767–72. https://doi.org/10.1016/j.cmi.2020.04.012

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Liu Z, Li J, Huang J, Guo L, Gao R, Luo K, et al. Association between Diabetes and COVID-19: a retrospective observational study with a large sample of 1,880 cases in Leishenshan Hospital, Wuhan. Front Endocrinol (Lausanne). 2020;11:478. https://doi.org/10.3389/fendo.2020.00478

    Article  CAS  PubMed  Google Scholar 

  4. National Health Commission of the People’s Republic of China. Diagnosis and treatment of COVID-19 (Trial Version 10). China Licensed Pharmacist. 2023;20(01):1–11. https://doi.org/10.3969/j.issn.2096-3327.2023.01.001

    Article  Google Scholar 

  5. Sha J, Meng C, Sun J, Sun L, Gu R, Liu J, et al. Clinical and upper airway characteristics of 3715 patients with the Omicron variant of SARS-Cov-2 in Changchun, China. J Infect Public Health. 2023;16(3):422–9. https://doi.org/10.1016/j.jiph.2023.01.013

    Article  PubMed  PubMed Central  Google Scholar 

  6. Yang L, Shao J, Bian Y, Wu H, Shi L, Zeng L, et al. Prevalence of type 2 diabetes mellitus among inland residents in China (2000–2014): a meta-analysis. J Diabetes Investig. 2016;7(6):845–52. https://doi.org/10.1111/jdi.12514

    Article  PubMed  PubMed Central  Google Scholar 

  7. Writing Group of Clinical Guidelines for the Prevention and Treatment of Type 2 Diabetes in the Elderly in China. Clinical guidelines for prevention and treatment of type 2 diabetes mellitus in the elderly in China (2022 edition). Chin J Intern Med. 2022;61(1):12–50. https://doi.org/10.3760/cma.j.cn112138-20211027-00751

    Article  Google Scholar 

  8. Gangadharan S, Parker S, Ahmed FW. Chest radiological finding of COVID-19 in patients with and without diabetes mellitus: differences in imaging finding. World J Radiol. 2022;14(1):13–8. https://doi.org/10.4329/wjr.v14.i1.13

    Article  PubMed  PubMed Central  Google Scholar 

  9. Rangankar V, Koganti DV, Lamghare P, Prabhu A, Dhulipala S, Patil P, et al. Correlation between CT severity scoring and diabetes Mellitus in patients with COVID-19 infection. Cureus. 2021;13(12):e20199. https://doi.org/10.7759/cureus.20199

    Article  PubMed  PubMed Central  Google Scholar 

  10. Lu X, Cui Z, Pan F, Li L, Li L, Liang B, et al. Glycemic status affects the severity of coronavirus disease 2019 in patients with diabetes mellitus: an observational study of CT radiological manifestations using an artificial intelligence algorithm. Acta Diabetol. 2021;58(5):575–86. https://doi.org/10.1007/s00592-020-01654-x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Zhang Y, Cui Y, Shen M, Zhang J, Liu B, Dai M, et al. Association of diabetes mellitus with disease severity and prognosis in COVID-19: a retrospective cohort study. Diabetes Res Clin Pract. 2020;165:108227. https://doi.org/10.1016/j.diabres.2020.108227

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Hilal K, Shahid J, Ameen A, Martins RS, Nankani A, Haq TU, et al. Correlation of computerized tomography (CT) severity score for COVID-19 Pneumonia with Clinical outcomes. J Ayub Med Coll Abbottabad. 2022;34(1):24–30. https://doi.org/10.55519/JAMC-01-9344

    Article  PubMed  Google Scholar 

  13. Lampasona V, Secchi M, Scavini M, Bazzigaluppi E, Brigatti C, Marzinotto I, et al. Antibody response to multiple antigens of SARS-CoV-2 in patients with diabetes: an observational cohort study. Diabetologia. 2020;63(12):2548–58. https://doi.org/10.1007/s00125-020-05284-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Kiselar JG, Wang X, Dubyak GR, El Sanadi C, Ghosh SK, Lundberg K, et al. Modification of β-Defensin-2 by Dicarbonyls Methylglyoxal and Glyoxal inhibits antibacterial and chemotactic function in Vitro. PLoS ONE. 2015;10(8):e0130533. https://doi.org/10.1371/journal.pone.0130533

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Yan Y, Yang F, Zhu X, Wang M, Sun Z, Zhao T, et al. Analysis of clinical features and pulmonary CT features of coronavirus disease 2019 (COVID-19) patients with diabetes mellitus. Endokrynol Pol. 2020;71(5):367–75. https://doi.org/10.5603/EP.a2020.0055

    Article  CAS  PubMed  Google Scholar 

  16. Gu X, Sha L, Zhang S, Shen D, Zhao W, Yi Y. Neutrophils and lymphocytes can help Distinguish Asymptomatic COVID-19 from moderate COVID-19. Front Cell Infect Microbiol. 2021;11:654272. https://doi.org/10.3389/fcimb.2021.654272

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Elmokadem AH, Mounir AM, Ramadan ZA, Elsedeiq M, Saleh GA. Comparison of chest CT severity scoring systems for COVID-19. Eur Radiol. 2022;32(5):3501–12. https://doi.org/10.1007/s00330-021-08432-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Agarwal N, Jain P, Khan TN, Raja A. A retrospective study of association of CT severity with clinical profile and outcomes of patients with COVID-19 in the second wave. J Clin Imaging Sci. 2022;12:17. https://doi.org/10.25259/JCIS_11_2022

    Article  PubMed  PubMed Central  Google Scholar 

  19. Wang J, Zhu X, Xu Z, Yang G, Mao G, Jia Y, et al. Clinical and CT findings of COVID-19: differences among three age groups. BMC Infect Dis. 2020;20(1):434. https://doi.org/10.1186/s12879-020-05154-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Cao B, Iredell J, Middleton P, Young N. Chest CT in COVID-19 patients: a clinical need. J Med Radiat Sci. 2023;70(1):40–5. https://doi.org/10.1002/jmrs.642

    Article  PubMed  PubMed Central  Google Scholar 

  21. Zhang H, Liu X, Yu P, Cheng M, Wang W, Sun Y, et al. Dynamic CT assessment of disease change and prognosis of patients with moderate COVID-19 pneumonia. J Xray Sci Technol. 2020;28(5):851–61. https://doi.org/10.3233/XST-200711

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time Course of Lung Changes at chest CT during recovery from Coronavirus Disease 2019 (COVID-19). Radiology. 2020;295(3):715–21. https://doi.org/10.1148/radiol.2020200370

    Article  PubMed  Google Scholar 

  23. Yu L, Xiao Y, Zhao Q. The clinical manifestations and chest high resolution CT findings of patients with COVID-19. J Practical Radiol. 2021;37(7):1081–5. https://doi.org/10.3969/j.issn.1002-1671.2021.07.009

    Article  Google Scholar 

  24. Chung M, Bernheim A, Mei X, Zhang N, Huang M, Zeng X, et al. CT imaging features of 2019 Novel Coronavirus (2019-nCoV). Radiology. 2020;295(1):202–7. https://doi.org/10.1148/radiol.2020200230

    Article  PubMed  Google Scholar 

  25. Yang R, Li X, Liu H, Zhen Y, Zhang X, Xiong Q, et al. Chest CT severity score: an Imaging Tool for assessing severe COVID-19. Radiol Cardiothorac Imaging. 2020;2(2):e200047. https://doi.org/10.1148/ryct.2020200047

    Article  PubMed  PubMed Central  Google Scholar 

  26. Dyusupova A, Faizova R, Yurkovskaya O, Belyaeva T, Terekhova T, Khismetova A, et al. Clinical characteristics and risk factors for disease severity and mortality of COVID-19 patients with diabetes mellitus in Kazakhstan: a nationwide study. Heliyon. 2021;7(3):e06561. https://doi.org/10.1016/j.heliyon.2021.e06561

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Bashir M, Inzamam W, Robbani I, Banday TR, Al-Misned FA, El-Serehy HA, et al. Patients with diabetes experienced more serious and protracted sickness from the COVID-19 infection: a prospective study. Med (Kaunas). 2023;59(3):472. https://doi.org/10.3390/medicina59030472

    Article  Google Scholar 

  28. Zakariaee SS, Salmanipour H, Naderi N, Kazemi-Arpanahi H, Shanbehzadeh M. Association of chest CT severity score with mortality of COVID-19 patients: a systematic review and meta-analysis. Clin Transl Imaging. 2022;10(6):663–76. https://doi.org/10.1007/s40336-022-00512-w

    Article  PubMed  PubMed Central  Google Scholar 

  29. Raoufi M, Khalili S, Mansouri M, Mahdavi A, Khalili N. Well-controlled vs poorly-controlled diabetes in patients with COVID-19: are there any differences in outcomes and imaging findings? Diabetes Res Clin Pract. 2020;166:108286. https://doi.org/10.1016/j.diabres.2020.108286

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This research did not receive any funding support.

Author information

Author notes

  1. Dan Lu and Yuhong Liu contributed equally to this work.

Authors and Affiliations

  1. Department of Radiology, Yan’an Hospital Affiliated to Kunming Medical University, No. 245 Renmin East Road, Panlong District, 650051, Kunming, Yunnan, China

    Dan Lu, Yuhong Liu, Pengcheng Ma, Rui Hou & Jin Wang

Authors
  1. Dan Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuhong Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pengcheng Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rui Hou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

(I) Conception and design: Lu D. (II) Administrative support: Liu YH and Ma PC. (III) Provision of study materials or patients: Hou R and Wang J. (IV) Collection and assembly of data: Liu YH and Hou R. (V) Data analysis and interpretation: Ma PC, Lu D and Wang J. (VI) Manuscript writing: All authors. (VII) Final approval of manuscript: All authors.

Corresponding author

Correspondence to Jin Wang.

Ethics declarations

Ethics approval and consent to participate

This study was conducted in accordance with the declaration of Helsinki.The studies involving human participants were reviewed and approved by the Yan’an Hospital Affiliated to Kunming Medical University. The patients/participants provided their written informed consent to participate in this study.

Consent for publication

The manuscript is not submitted for publication or consideration elsewhere.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lu, D., Liu, Y., Ma, P. et al. Severity of COVID-19 infection in patients with COVID-19 combined with diabetes. J Health Popul Nutr 43, 55 (2024). https://doi.org/10.1186/s41043-024-00548-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s41043-024-00548-w

Keywords

Journal of Health, Population and Nutrition

ISSN: 2072-1315

Contact us